Human papillomavirus type 16 genomic DNA (HPV-16 DNA) (HPV-16 DNA)

Human papillomavirus type 16 (HPV-16) genomic DNA is the primary etiologic agent in the development of approximately 50-60% of cervical cancers worldwide (WHO, 2020). In infected cervical epithelial cells, the ~8kb circular double-stranded DNA genome exists as an episome during early-stage infection but frequently integrates into the host genome during the progression to high-grade squamous intraepithelial lesions and invasive carcinoma (NIH, 2023). This integration often results in the loss of the E2 regulatory gene, leading to the constitutive overexpression of the E6 and E7 oncogenes (PubMed, PMID: 28438882). These oncogenes facilitate the degradation of host tumor suppressors p53 and pRb, driving malignant transformation (UniProt, 2024). While traditional therapies focus on lesion removal, the HPV-16 DNA itself is an emerging target for molecular therapeutics, including CRISPR/Cas9 systems designed to cleave viral sequences and antisense oligonucleotides aimed at silencing viral gene expression (PubMed, PMID: 30154076). Targeting the genomic DNA provides a strategy to permanently disrupt the viral life cycle and reverse the oncogenic phenotype of infected cells (StatPearls, 2023). This approach aims to eliminate the source of oncogenic protein production, thereby inducing apoptosis in transformed cells and preventing the progression of pre-cancerous lesions to invasive carcinoma.

Other names

HPV16 genomeHuman papillomavirus 16 DNAHPV-16 episomeIntegrated HPV-16 DNA

Direct cleavage of viral oncogenic sequences (E6/E7) or inhibition of viral DNA synthesis to prevent cellular transformation and viral persistence.